OSE Immunotherapeutics has received a French government grant to support a Phase III clinical trial for its cancer vaccine, Tedopi. The trial will focus on patients with advanced non-small cell lung cancer (NSCLC) who have not responded to previous treatments. Tedopi is designed to stimulate the immune system to target specific tumor cells, offering a new potential treatment option for those with limited alternatives. The funding underscores France’s commitment to advancing innovative cancer therapies.
French biotech wins funding for an advanced lung cancer vaccine trial
Help us improve this article
- Add a clear point? Share it in comment.
- Spot an error? Provide the correction and source.
- Broken link? Share a working alternative.
Your feedback helps keep the content accurate and valuable.
